Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Drops By 68.5%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totaling 6,757 shares, a decrease of 68.5% from the April 30th total of 21,481 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average daily volume of 32,441 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Investors Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Bluejay Diagnostics Price Performance

Shares of Bluejay Diagnostics stock traded down $0.04 during trading hours on Friday, reaching $2.14. The company had a trading volume of 108,146 shares, compared to its average volume of 69,387. The firm has a market cap of $2.20 million, a PE ratio of -0.18 and a beta of 0.72. Bluejay Diagnostics has a one year low of $1.62 and a one year high of $16.68. The business has a fifty day simple moving average of $1.90 and a 200 day simple moving average of $2.87.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.